To the Editor Dr Smith and colleagues1 concluded that “among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain.”
The overall strength of effect underpinning this conclusion, however, is relatively small, despite reaching statistical significance. The authors most clearly demonstrated this in Figure 2 in the article, which shows closely approximated or overlapping confidence intervals in both the initial and crossover treatment periods.
Seretny M, Colvin L, Fallon M. Therapy for Chemotherapy-Induced Peripheral Neuropathy. JAMA. 2013;310(5):537-538. doi:10.1001/jama.2013.7902